Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RADOO1 (Everolimus)
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Bevacizumab (Primary) ; Everolimus (Primary)
- Indications Renal cancer
- Focus Biomarker; Therapeutic Use
- 08 Jun 2010 Study details were reported at ASCO 2010.
- 02 Sep 2009 Planned end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 02 Sep 2009 Actual initiation date (Aug 2008) added as reported by ClinicalTrials.gov.